$0.6003
0.002300.38%
At close: -
$0.6200
0.023.28%
After Hours: 6:32 PM EDT
Comments
Loading...
Unicycive Therapeutics Analyst Ratings and Price Targets | NASDAQ:UNCY | Benzinga
Unicycive Therapeutics Inc has a consensus price target of $6.08 based on the ratings of 6 analysts. The high is $9 issued by Piper Sandler on April 4, 2024. The low is $3 issued by Benchmark on November 22, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 11, 2025, April 1, 2025, and January 29, 2025, respectively. With an average price target of $6.33 between HC Wainwright & Co., there's an implied 921.51% upside for Unicycive Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Benchmark
Piper Sandler
Noble Capital Markets
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Unicycive Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/11/2025 | Buy Now | 1109.68% | HC Wainwright & Co. | Ed Arce56% | $7.5 → $7.5 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2025 | Buy Now | 1109.68% | HC Wainwright & Co. | Ed Arce56% | $4 → $7.5 | Maintains | Buy | Get Alert |
| 01/29/2025 | Buy Now | 545.16% | HC Wainwright & Co. | Ed Arce56% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 545.16% | HC Wainwright & Co. | Ed Arce56% | $4 → $4 | Maintains | Buy | Get Alert |
| 11/22/2024 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | $3 → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 11/14/2024 | Buy Now | 545.16% | HC Wainwright & Co. | Ed Arce56% | $2.5 → $4 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 303.23% | HC Wainwright & Co. | Ed Arce56% | $2.5 → $2.5 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2024 | Buy Now | 303.23% | HC Wainwright & Co. | Ed Arce56% | $2.5 → $2.5 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2024 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | $3 → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 09/03/2024 | Buy Now | 303.23% | HC Wainwright & Co. | Ed Arce56% | $2.5 → $2.5 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2024 | Buy Now | 303.23% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $2.5 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 06/25/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | $3 → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 05/31/2024 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | $3 → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 05/29/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 04/15/2024 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | $3 → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 04/04/2024 | Buy Now | 1351.61% | Piper Sandler | Yasmeen Rahimi55% | → $9 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2024 | Buy Now | 867.74% | Noble Capital Markets | Robert LeBoyer43% | → $6 | Initiates | → Outperform | Get Alert |
| 12/19/2023 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $4.5 → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 08/16/2023 | Buy Now | 625.81% | HC Wainwright & Co. | Ed Arce56% | $7 → $4.5 | Maintains | Buy | Get Alert |
| 07/19/2023 | Buy Now | 1029.03% | HC Wainwright & Co. | Ed Arce56% | → $7 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 706.45% | EF Hutton | Elemer Piros55% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 1029.03% | HC Wainwright & Co. | Ed Arce56% | $8 → $7 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 1190.32% | HC Wainwright & Co. | Ed Arce56% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 05/17/2023 | Buy Now | 1190.32% | HC Wainwright & Co. | Ed Arce56% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | Buy Now | 706.45% | EF Hutton | Elemer Piros55% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2023 | Buy Now | 383.87% | Benchmark | Bruce Jackson39% | $13 → $3 | Maintains | Speculative Buy | Get Alert |
| 04/03/2023 | Buy Now | 1190.32% | HC Wainwright & Co. | Ed Arce56% | → $8 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | 3770.97% | EF Hutton | Elemer Piros55% | → $24 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 706.45% | EF Hutton | Elemer Piros55% | → $5 | Initiates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 1190.32% | HC Wainwright & Co. | Ed Arce56% | → $8 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 867.74% | Maxim Group | Jason McCarthy41% | $3 → $6 | Maintains | Buy | Get Alert |
| 11/28/2022 | Buy Now | 1190.32% | HC Wainwright & Co. | Ed Arce56% | $9 → $8 | Maintains | Buy | Get Alert |
| 06/08/2022 | Buy Now | 1351.61% | HC Wainwright & Co. | Ed Arce56% | → $9 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Unicycive Therapeutics (UNCY) stock?
The latest price target for Unicycive Therapeutics (NASDAQ:UNCY) was reported by HC Wainwright & Co. on April 11, 2025. The analyst firm set a price target for $7.50 expecting UNCY to rise to within 12 months (a possible 1109.68% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Unicycive Therapeutics (UNCY)?
The latest analyst rating for Unicycive Therapeutics (NASDAQ:UNCY) was provided by HC Wainwright & Co., and Unicycive Therapeutics reiterated their buy rating.
When was the last upgrade for Unicycive Therapeutics (UNCY)?
There is no last upgrade for Unicycive Therapeutics
When was the last downgrade for Unicycive Therapeutics (UNCY)?
There is no last downgrade for Unicycive Therapeutics.
When is the next analyst rating going to be posted or updated for Unicycive Therapeutics (UNCY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unicycive Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unicycive Therapeutics was filed on April 11, 2025 so you should expect the next rating to be made available sometime around April 11, 2026.
Is the Analyst Rating Unicycive Therapeutics (UNCY) correct?
While ratings are subjective and will change, the latest Unicycive Therapeutics (UNCY) rating was a reiterated with a price target of $7.50 to $7.50. The current price Unicycive Therapeutics (UNCY) is trading at is $0.62, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
